163 related articles for article (PubMed ID: 29237725)
21. Opioid-induced mitogen-activated protein kinase signaling in rat enteric neurons following chronic morphine treatment.
Duraffourd C; Kumala E; Anselmi L; Brecha NC; Sternini C
PLoS One; 2014; 9(10):e110230. PubMed ID: 25302800
[TBL] [Abstract][Full Text] [Related]
22. Differential activation of G-proteins by mu-opioid receptor agonists.
Saidak Z; Blake-Palmer K; Hay DL; Northup JK; Glass M
Br J Pharmacol; 2006 Mar; 147(6):671-80. PubMed ID: 16415903
[TBL] [Abstract][Full Text] [Related]
23. Mu opioid receptor mutant, T394A, abolishes opioid-mediated adenylyl cyclase superactivation.
Wang H; Guang W; Barbier E; Shapiro P; Wang JB
Neuroreport; 2007 Dec; 18(18):1969-73. PubMed ID: 18007196
[TBL] [Abstract][Full Text] [Related]
24. RGS14 prevents morphine from internalizing Mu-opioid receptors in periaqueductal gray neurons.
Rodríguez-Muñoz M; de la Torre-Madrid E; Gaitán G; Sánchez-Blázquez P; Garzón J
Cell Signal; 2007 Dec; 19(12):2558-71. PubMed ID: 17825524
[TBL] [Abstract][Full Text] [Related]
25. Agonist-induced, G protein-dependent and -independent down-regulation of the mu opioid receptor. The receptor is a direct substrate for protein-tyrosine kinase.
Pak Y; O'Dowd BF; Wang JB; George SR
J Biol Chem; 1999 Sep; 274(39):27610-6. PubMed ID: 10488100
[TBL] [Abstract][Full Text] [Related]
26. Plasma membrane localization of the μ-opioid receptor controls spatiotemporal signaling.
Halls ML; Yeatman HR; Nowell CJ; Thompson GL; Gondin AB; Civciristov S; Bunnett NW; Lambert NA; Poole DP; Canals M
Sci Signal; 2016 Feb; 9(414):ra16. PubMed ID: 26861044
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy.
Clayton CC; Bruchas MR; Lee ML; Chavkin C
Mol Pharmacol; 2010 Mar; 77(3):339-47. PubMed ID: 19959593
[TBL] [Abstract][Full Text] [Related]
28. Hetero-oligomers of alpha2A-adrenergic and mu-opioid receptors do not lead to transactivation of G-proteins or altered endocytosis profiles.
Zhang YQ; Limbird LE
Biochem Soc Trans; 2004 Nov; 32(Pt 5):856-60. PubMed ID: 15494033
[TBL] [Abstract][Full Text] [Related]
29. Chronic antidepressant treatment causes a selective reduction of mu-opioid receptor binding and functional coupling to G Proteins in the amygdala of fawn-hooded rats.
Chen F; Lawrence AJ
J Pharmacol Exp Ther; 2004 Sep; 310(3):1020-6. PubMed ID: 15121763
[TBL] [Abstract][Full Text] [Related]
30. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
Clark MJ; Traynor JR
J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
[TBL] [Abstract][Full Text] [Related]
31. Effects of chronic opioid exposure on guinea pig mu opioid receptor in Chinese hamster ovary cells: comparison with human and rat receptor.
Wallisch M; Nelson CS; Mulvaney JM; Hernandez HS; Smith SA; Olsen GD
Biochem Pharmacol; 2007 Jun; 73(11):1818-28. PubMed ID: 17343833
[TBL] [Abstract][Full Text] [Related]
32. Endogenous RGS protein action modulates mu-opioid signaling through Galphao. Effects on adenylyl cyclase, extracellular signal-regulated kinases, and intracellular calcium pathways.
Clark MJ; Harrison C; Zhong H; Neubig RR; Traynor JR
J Biol Chem; 2003 Mar; 278(11):9418-25. PubMed ID: 12524446
[TBL] [Abstract][Full Text] [Related]
33. Salvinorin A: allosteric interactions at the mu-opioid receptor.
Rothman RB; Murphy DL; Xu H; Godin JA; Dersch CM; Partilla JS; Tidgewell K; Schmidt M; Prisinzano TE
J Pharmacol Exp Ther; 2007 Feb; 320(2):801-10. PubMed ID: 17060492
[TBL] [Abstract][Full Text] [Related]
34. Noladin ether, a putative endocannabinoid, inhibits mu-opioid receptor activation via CB2 cannabinoid receptors.
Páldyová E; Bereczki E; Sántha M; Wenger T; Borsodi A; Benyhe S
Neurochem Int; 2008 Jan; 52(1-2):321-8. PubMed ID: 17698254
[TBL] [Abstract][Full Text] [Related]
35. Involvement of kappa opioid receptors in the inhibition of receptor desensitization and PKC activation induced by repeated morphine treatment.
Hamabe W; Yamane H; Harada S; Tokuyama S
J Pharm Pharmacol; 2008 Sep; 60(9):1183-8. PubMed ID: 18718122
[TBL] [Abstract][Full Text] [Related]
36. Ligand-selective activation of mu-oid receptor: demonstrated with deletion and single amino acid mutations of third intracellular loop domain.
Chaipatikul V; Loh HH; Law PY
J Pharmacol Exp Ther; 2003 Jun; 305(3):909-18. PubMed ID: 12626655
[TBL] [Abstract][Full Text] [Related]
37. Functional characterization of human variants of the mu-opioid receptor gene.
Ravindranathan A; Joslyn G; Robertson M; Schuckit MA; Whistler JL; White RL
Proc Natl Acad Sci U S A; 2009 Jun; 106(26):10811-6. PubMed ID: 19528663
[TBL] [Abstract][Full Text] [Related]
38. Absence of G-protein activation by mu-opioid receptor agonists in the spinal cord of mu-opioid receptor knockout mice.
Narita M; Mizoguchi H; Narita M; Sora I; Uhl GR; Tseng LF
Br J Pharmacol; 1999 Jan; 126(2):451-6. PubMed ID: 10077238
[TBL] [Abstract][Full Text] [Related]
39. Loss of mu-opioid receptor-mediated G-protein activation in the pons/medulla of mice lacking the exons 2 and 3 of mu-opioid receptor gene.
Mizoguchi H; Wu HE; Narita M; Loh HH; Nagase H; Tseng LF
Neurosci Lett; 2002 Dec; 335(2):91-4. PubMed ID: 12459506
[TBL] [Abstract][Full Text] [Related]
40. Agonist activity of naloxone benzoylhydrazone at recombinant and native opioid receptors.
Olianas MC; Concas D; Onali P
Br J Pharmacol; 2006 Feb; 147(4):360-70. PubMed ID: 16402046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
